159753-13-6

Upstream product

• 119-32-4 4-Methyl-3-nitroanilin 
• 815603-43-1 1-acetyl-3-(4-methyl-3-nitro-phenyl)thiourea 
• 347909-29-9 N-(4-methyl-3-nitro-phenyl)-N'-phenyl-thiourea 
• 321898-79-7 4-methyl-3-nitro-phenyl isothiocyanate 

Downstream Products

• 1215916-41-8 4-methyl-N₁-thiazol-2-yl-benzene-1,3-diamine 
• 1420998-38-4 N-[5-(acetyl-thiazol-2-yl-amino)-2-methyl-phenyl]acetamide 
• 1420998-39-5 N-{3-[5-(3-bromo-5-isopropoxy-phenyl)oxazol-2-ylamino]-4-methyl-phenyl}-N-thiazol-2-yl-acetamide 
• 1420997-73-4 C₂₅H₂₆N₆O₃S 
• 1420998-36-2 (4-methyl-3-nitro-phenyl)thiourea 
• 21352-58-9 2,7-bis-(4-methyl-3-nitro-anilino)-1,6-dithia-3,8-diaza-spiro[4.4]nona-2,7-diene-4,9-dione 

Relevant academic research and scientific papers

OXAZOLE AND THIAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS (C-KIT)

The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, A, Q, W and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.